/PRNewswire/ Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the.
Leadless ICD Exceeds Safety, Performance Expectations miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM Subcutaneous Implantable Defibrillator and EMPOWER Leadless Pacemaker
In recent months, Abbott Laboratories unveiled a dual-chamber model of the leadless pacemaker, overcoming the atrial limitations of the single-chamber model.